Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SS-POR11
- Development stage
- Unknown
- Lead developer
- S Biomedic
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
SS-POR11 is a topical live biotherapeutic product (LBP) consisting of a proprietary probiotic strain of *Cutibacterium acnes* (formerly *Propionibacterium acnes*). Developed by S-Biomedic in collaboration with DSM Nutritional Products, and subsequently part of the Beiersdorf portfolio following their acquisition of S-Biomedic in 2022, SS-POR11 is designed to treat acne vulgaris by modulating the skin microbiome. The therapy works by introducing a beneficial, non-inflammatory strain of *C. acnes* to displace pathogenic or pro-inflammatory phylotypes associated with acne. A primary focus of its clinical evaluation is the reduction of follicular porphyrins—metabolic byproducts of certain *C. acnes* strains that are known to induce oxidative stress and trigger inflammatory responses in the skin. By altering the microbial composition and reducing porphyrin levels, SS-POR11 aims to alleviate the inflammatory lesions characteristic of acne.
- Other names
- SS-POR11 probiotic strainSS-POR-11 probiotic strainSS-POR 11 probiotic strainS-Biomedic probiotic
Beyond the preview
Go deeper on SS-POR11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SS-POR11.